Company Overview of Andrx Corporation
Andrx Corporation is a holding company which through its subsidiaries develops, manufactures, commercializes, and distributes generic versions of controlled-release pharmaceuticals, oral contraceptives, and generic versions of immediate-release products. The company also develops and commercializes brand name pharmaceuticals; and distributes primarily generics that are commercialized by others and its own products. In addition, it offers contract services such as development and manufacture of pharmaceutical products including combination products and controlled-release formulations for other pharmaceutical companies; and contract research and development services. It also markets generic pr...
4955 Orange Drive
Davie, FL 33314
Founded in 1992
Key Executives for Andrx Corporation
Chief Information Officer, Senior Vice President and Head of Project Management Office
Executive Vice President of Commercial Development
Compensation as of Fiscal Year 2015.
Andrx Corporation Key Developments
Orexigen Therapeutics, Inc. and Takeda Pharmaceuticals File Lawsuit against Actavis Laboratories FL, Inc., Andrx Corporation, Actavis Pharma, Inc. and Actavis Inc. For Infringement of Contrave Patents
Jun 5 15
Orexigen Therapeutics, Inc. announced that it and its North American partner, Takeda Pharmaceuticals, have filed a lawsuit in the U.S. District Court for the District of Delaware against Actavis Laboratories FL, Inc., Andrx Corporation, Actavis Pharma, Inc., and Actavis Inc., collectively referred to as Actavis. The lawsuit was filed in response to an Abbreviated New Drug Application, or ANDA, filed by Actavis. In its application, Actavis seeks to market and sell generic versions of the currently approved doses of Contrave (naltrexone HCl /bupropion HCl extended release) tablets prior to the expiration of U.S. Patents listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. Takeda and Orexigen filed the lawsuit on the basis that Actavis' proposed generic products infringe each of these patents.
Galena Biopharma's Partner Orexo Files Patent Infringement Suit Against Actavis Laboratories, Andrx Corporation, Actavis, Inc. and Actavis Pharma
Feb 5 15
Galena Biopharma (GALE) announced that its partner Orexo has filed a patent infringement lawsuit in United States District Court for the District of New Jersey, against Actavis Laboratories, Andrx Corporation, Actavis Inc. (ACT) and Actavis Pharma for seeking to market a generic version of its Abstral drug. The lawsuit was filed in response to an Abbreviated New Drug Application filed by Actavis. In its application, Actavis seeks to market and sell generic versions of Abstral sublingual tablets in the U.S. prior to the expiration of Orexo's U.S. patents.
Horizon Pharma, Inc. Files Suit in United States District Court for the District of New Jersey Against Watson Laboratories, Inc., Actavis Pharma, Inc., Andrx Corp., and Actavis, Inc
Aug 28 13
On August 26, 2013, Horizon Pharma, Inc. filed suit in the United States District Court for the District of New Jersey against Watson Laboratories, Inc. - Florida, Actavis Pharma, Inc., Andrx Corp., and Actavis, Inc. (collectively, WLF). The lawsuit alleges that WLF has infringed U.S. Patent Nos. 6,488,960, 6,677,326, 8,168,218, 8,309,124, and 8,394,407 by filing an Abbreviated New Drug Application (ANDA) seeking approval from the U.S. Food and Drug Administration (FDA) to market generic versions of RAYOS containing 1 mg, 2 mg, and 5 mg of prednisone prior to the expiration of the patents. The subject patents are listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Commencement of the patent infringement lawsuit stays, or bars, FDA approval of WLF's ANDA for 30 months or until an earlier district court decision that the subject patents are not infringed or invalid.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|